{"entity":{"id":"nct06592326","kind":"trial","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","aka":[],"tldr":"A phase 3 trial of Toripalimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06592326 by Mabwell (Shanghai) Bioscience Co., Ltd., with 460 participants planned, started 2024-08-22 and due to reach its primary completion in 2027-09. Interventions recorded: 9MW2821, Toripalimab, Gemcitabine and Cisplatin/Carboplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06592326","url":"https://clinicaltrials.gov/study/NCT06592326"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab","gemcitabine","carboplatin","cisplatin"],"companies":["mabwell-shanghai-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06592326","phase":"3","setting":"A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","started":"2024-08-22","startedType":"actual","enrolled":460,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06592326/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/"}]}}